Učitavanje...
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunotherapy has evolved as a new pillar of cancer treatment during the last decade. The main breakthrough was the development of immune checkpoint blocking (ICB) antibodies, which antagonize inhibitory receptors on T cells and their ligands and thus unleash the cellular immune system against the t...
Spremljeno u:
| Izdano u: | EMBO Mol Med |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5286364/ https://ncbi.nlm.nih.gov/pubmed/27965270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607219 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|